Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Koki Taniguchi has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Generation of Recombinant Authentic Live Attenuated Human Rotavirus Vaccine Strain RIX4414 (Rotarix®) from Cloned cDNAs Using Reverse Genetics

    by Saori Fukuda, Masanori Kugita, Kanako Kumamoto, Yuki Akari, Yuki Higashimoto, Shizuko Nagao, Takayuki Murata, Tetsushi Yoshikawa, Koki Taniguchi, Satoshi Komoto

    The live attenuated human rotavirus vaccine strain RIX4414 (Rotarix®) is used worldwide to prevent severe rotavirus-induced diarrhea in infants. This strain was attenuated through the cell culture passaging of its predecessor, human strain 89-12, which resulted in multiple genomic mutations. However, the specific molecular reasons underlying its attenuation have remained elusive, primarily due to the absence of a suitable reverse genetics system enabling precise genetic manipulations. Therefore, we first completed the sequencing of its genome and then developed a reverse genetics system for the authentic RIX4414 virus. Our experimental results demonstrate that the rescued recombinant RIX4414 virus exhibits biological characteristics similar to those of the parental RIX4414 virus, both in vitro and in vivo. This novel reverse genetics system provides a powerful tool for investigating the molecular basis of RIX4414 attenuation and may facilitate the rational design of safer and more effective human rotavirus vaccines.


  • Open Access

    Human Rotavirus Reverse Genetics Systems to Study Viral Replication and Pathogenesis

    by Satoshi Komoto, Saori Fukuda, Takayuki Murata, Koki Taniguchi

    Human rotaviruses (HuRVAs) are highly important causes of acute gastroenteritis in infants and young children worldwide. A lack of reliable and reproducible reverse genetics systems for HuRVAs has limited a proper understanding of HuRVA biology and also the rational design of live-attenuated vaccines. Since the development of the first reverse genetics system for RVAs (partially plasmid-based reverse genetics system) in 2006, there have been many efforts with the goal of generating infectious recombinant HuRVAs entirely from cloned cDNAs. However, the establishment of a HuRVA reverse genetics system was very challenging until 2019. This review article provides an overview of the historical background of the recent development of long-awaited HuRVA reverse genetics systems, beginning with the generation of recombinant human-simian reassortant RVAs with the aid of a helper virus in 2006 and the generation of recombinant animal (simian) RVAs in a helper virus-free manner in 2017, and culminating in the generation of recombinant HuRVAs entirely from plasmid cDNAs in 2019. Notably, the original HuRVA reverse genetics system has already been optimized to increase the efficiency of virus generation. Although the application of HuRVA reverse genetics systems has only just been initiated, these technologies will help to answer HuRVA research questions regarding viral replication and pathogenicity that could not be addressed before, and to develop next-generation vaccines and intestine-specific rotaviral vectors.


  • Open Access

    Variation in rotavirus vaccine coverage by sub-counties in Kenya

    by Ernest Apondi Wandera, Shah Mohammad, John Odhiambo Ouko, James Yatitch, Koki Taniguchi, Yoshio Ichinose

    Rotavirus gastroenteritis is an important cause of childhood morbidity and mortality in Kenya. In July 2014, Kenya introduced the rotavirus vaccine into her national immunization program. Although immunization coverage is crucial in assessing the real-world impact of this vaccine, variability in the vaccine coverage across the country is likely to occur. In view of this, we estimated the extent of coverage for the rotavirus vaccine at two socio-economically different sub-counties using the administrative data. The findings indicate disparities in vaccine coverage and access between the sub-counties and, thus, underscore the need to strengthen immunization systems to facilitate timely, accessible, and equitable vaccine delivery across the country. Both sub-counties recorded high vaccine dropout, suggestive of poor utilization of the vaccine. In this regard, increased social mobilization is needed to encourage vaccine compliance and to enhance tracking of vaccine defaulters. While efforts to improve the accuracy of the administrative coverage estimates are crucial, vaccination coverage surveys will be needed to verify the administrative coverage data and help identify specific factors relating to rotavirus vaccine coverage in the country.


  • Molecular epidemiology of rotavirus gastroenteritis in Central Kenya before vaccine introduction, 2009-2014

    by Ernest A. Wandera, Shah Mohammad, Satoshi Komoto, Yoshimasa Maeno, James Nyangao, Tomihiko Ide, Cyrus Kathiiko, Erick Odoyo, Takao Tsuji, Koki Taniguchi, et al.


  • Predominant prevalence of human rotaviruses with the G1P[8] and G8P[8] genotypes with a short RNA profile in 2013 and 2014 in Sukhothai and Phetchaboon provinces, Thailand

    by Ratigorn Guntapong, Ratana Tacharoenmuang, Phakapun Singchai, Sompong Upachai, Karun Sutthiwarakom, Satoshi Komoto, Takao Tsuji, Piyanit Tharmaphornpilas, Tetsushi Yoshikawa, Somchai Sangkitporn, et al.

    Of 2,754 stool specimens collected from children with acute gastroenteritis during 2013–2014 in Sukhothai and Phetchaboon provinces, Thailand, 666 (24.2%) were positive for rotavirus A (RVA) in polyacrylamide gel electrophoresis (PAGE). The G and P types of all RVA‐positive specimens were determined by semi‐nested RT‐PCR. G1P[8] (56.5%) was most prevalent, followed by G2P[4] (22.1%). Unusual G8P[8] human RVAs (HuRVAs) were detected at a high frequency (20.0%). Interestingly, 171 of the 376 G1P[8] HuRVAs and all of the 133 G8P[8] HuRVAs showed a short RNA pattern in PAGE. Thus, it was shown that the properties of HuRVAs have been markedly unusual in recent years in Thailand. J. Med. Virol. 89:615–620, 2017.


  • Genetics and reverse genetics of rotavirus

    by Koki Taniguchi, Satoshi Komoto


  • Human rotavirus vaccine

    by Koki Taniguchi

    2006年に2種のヒトロタウイルスワクチン(RotarixとRotaTeq)のすぐれた有効性と安全性を示す臨床試験成績が報告されて以来,ロタウイルスワクチンに対する関心は大いに高まった.これらのワクチンは100ヵ国以上で認可され,約30ヵ国で定期接種されている.防御能は期待以上であり,重症ロタウイルス下痢症乳児の大幅な減少につながった.わが国においても,昨年11月にRotarixの投与が開始され,RotaTeqについても間もなく開始される.これら2種のヒトロタウイルスワクチンの組成,特徴,実際の効果について記載し,腸重積,感染防御の機構,ワクチン株の排泄の意味など,問題点を含めた今後の展望についてまとめた.


  • Open Access

    Porcine Rotavirus Closely Related to Novel Group of Human Rotaviruses

    by Mitsutaka Wakuda, Tomihiko Ide, Jun Sasaki, Satoshi Komoto, Junichi Ishii, Takeshi Sanekata, Koki Taniguchi

    We determined nucleotide sequences and inferred amino acid sequences of viral protein (VP) 4, VP6, VP7, and nonstructural protein 4 genes of a porcine rotavirus strain (SKA-1) from Japan. The strain was closely related to a novel group of human rotavirus strains (B219 and J19).


  • A long‐term survey on the distribution of the human rotavirus G type in Thailand

    by Yaowapa Pongsuwannna, Ratigorn Guntapong, Ratana Tacharoenmuang, Malliga Prapanpoj, Masanori Kameoka, Koki Taniguchi

    The distribution of the G type of human rotavirus was surveyed in Thailand between July 1993 and June 2007. A significant yearly change in the distribution of the G type distribution was found. From 1993–1994 to 1998–1999, the G1 type was the most dominant. In 1999–2000, G9 began to appear at a high frequency. In 2000–2001, 2001–2002, and 2002–2003, G9 was very common. In 2003–2004, G1 became the most prevalent type again, and since then it has been detected at the highest frequency. G12 strains, which were first detected in 1998–1999, were also found in 2004–2005 and 2006–2007. The G4 and G3 types were moderately prevalent in 2001–2002 and 2004–2005, respectively. Nucleotide sequence analysis of the VP7 genes of the G9 and G12 strains which reemerged in Thailand showed that they were each similar to the contemporary strains in other countries. J. Med. Virol. 82:157–163, 2010.


  • Present and future of reverse genetics of rotavirus

    by Koki Taniguchi, Satoshi Komoto, Jun Sasaki, Masanori Kugita

    Rotavirus is the leading pathogen for acute gastroenteritis in mammals and birds. Although the reverse genetics system has been utilized in many viruses, the system using a helper virus was developed for rotavirus in 2006. As a step for antigenic analysis of VP4 antigen of rotavirus, we prepared an infectious rotavirus with a spike protein VP4 having an antigenic mosaic by substituting one of the cross-reactive neutralization epitopes of a simian strain SA-11 with the corresponding one of a human strain DS-1. The future improvement and application of the rotavirus reverse genetics were discussed in this review.